Oregon Drug Use Review Board

Meeting Minutes
Tuesday, November 18, 2003; 2:00-5:00 PM
Human Resources Building Rm 352
500 Summer Street NE - Salem, OR

I. Call to order

a. **Members present**: Gregory Johnson, MD; Robert Ingle, MD; Patrick Bowman, RPh; Rickland Asai, DMD; Gerald Fairbanks, RPh, Sharon Leigh, PharmD; Christina Heinrich, PharmD; Raymond Lee, MD; Robert Mendelson, MD (via phone at 2:30); and Cliff Singer, MD at 3:00 PM.
Members absent: Dean Haxby, PharmD and John Muench, MD, MPH; Staff present: Kathy Ketchum (OSU), Dan Hartung (OSU), Tom Turek, MD (OMAP), Rose-Ellen Hope (FHSC) and Tom Drawbaugh (OMAP).
Guests present: Dennis Sagendorf (Purdue) and Tracey Davies (Lilly).

b. A quorum was present and meeting was called to order at 2:05 PM by Chairman Gregory Johnson.

c. The minutes were approved with no corrections and agenda was approved with additions to the agenda packet materials.

d. The Conflict of Interest Declaration was reviewed and renewed.

e. There was no public comment.

II. Old Business

a. **OMAP provider identification**
Ms. Ketchum reported that this was not possible to use the provider license number because of the diversity of formats used by the different licensing organizations. This issue is prominent in the new MMIS procurement which is mid-way in a 5 year process.

b. **Triptan quantity limits**
Ms. Ketchum reported that OMAP is planning to implement this recommendation on December 1, 2003 and presented the provider and patient communications that have been sent.

c. **Growth Hormone Criteria**
Ms. Ketchum reported that OMAP implemented this criteria change on October 1. There have been no calls regarding this action thus far.

d. **Proposed Emend PA Criteria**

The Board reviewed the criteria.

Action: The Board recommended the criteria be adopted as written.

e. **Proposed FluMist PA Criteria**
The Board reviewed the criteria.

Action: The Board recommended the criteria be adopted as written.

f. **Xolar follow up**
Ms. Ketchum reported this issue was forwarded to OMAP's Asthma DSM program for monitoring.

g. **Meeting Dates**
Meeting dates are confirmed for Tuesdays 2-5 PM on 2/24/2004 (Rm 137AB), 5/25/2004 (Rm 137AB), 9/14/2004 (Rm 473) and 11/30/2004 (Rm 137AB)

III. Reports

a. **Drug Cost PMPM Report**
The DUR Board reviewed the report.

b. **Generic Use Report**
The DUR Board reviewed the report.

c. **ProDUR Alert Report by Class** (tabled)

d. **ProDUR Report**
Ms. Hope reported that First Health's new point of sale claim processing system (First SX) which was implemented 12/6/02 is now able to customize messaging to DUR Board actions. First Health is starting the process of aligning messages to past DUR Board actions. The drug interaction severity is based on First DataBank ranking. The Board reviewed top 3 messages in categories.

Action: Turn off levothyroxine-cardiovascular disease alert.

Action: Review antidepressant alerts for next meeting.

e. **RetroDUR Report**
Ms. Hope reported a response rate of 74% and much increased response of discontinued drug (32%). The DUR Council was uncomfortable lettering on antidepressant use in children as the DUR Board had recommended last meeting. Wellpartner has the largest number of claims with default provider numbers.

Action: A review of the literature on suicide risk in children on SSRI antidepressants to be prepared for February's meeting.

Action: Wellpartner will be notified regarding the provider ID issue.

f. **Education Report**
Ms. Ketchum presented examples of provider letters on PDL classes that are planned to go out in November. The October issue was on Flumist. Future articles include: a review of Xolair, a review of Prilosec OTC and a review of the drug therapy for senile dementia.

g. **HRC Report**
Ms. Ketchum reported that updates of the original four classes have been completed and there have been adjustments to the lists effective on Nov. 1. The calcium channel blocker and ACE inhibitor classes have recently been completed. Beta-blockers will likely be complete by the end of the year.

h. **Pharmacy Program Update**
Mr. Drawbaugh reviewed the program changes since September. There was a change in the exception process for the PDL on October 1, 2003. The state was directed by the legislature not to use the phone call exception process. Four new classes were added to the PDL on November 1, 2003. Some adjustments were made to the long-acting opioids, NSAIDs and PPI classes based on the updated reviews. Gabapentin became a managed care responsibility on October 1. At the same time the grandfather period for the fee-for-service PA ended. The mental health “frozen list” was abolished on October 1. The Board was updated on ongoing claims processing issues being addressed by OMAP and First Health. The Board was also updated on coordination of benefits issues.

IV. New Business

a. **Thiazolidinedione Class Review**
Dr. Hartung presented a literature review, claims analysis and study evaluating heart failure risk with thiazolidinediones.

Action: Retrospective education recommended on this issue.

b. **Antibiotic prescribing in upper respiratory infections**
Ms. Ketchum presented a drug use evaluation reflecting preliminary data compiled for the Health Department’s Judicious Use of Antibiotics project that suggests widespread antibiotic use for predominantly viral infections. She reported the health department is planning an intervention to address this.

Action: DUR Newsletter article on issue is recommended.

c. **Polypharmacy Proposal**
Dr. Turek presented historical background and proposal. The proposal does ask the DUR Board members to assist Dr. Turek with evaluation of the appropriateness of drug therapies.

Action: DUR Board members agreed to participate in this project.

Meeting was adjourned at 4:05 PM by Chairman Gregory Johnson.

Minutes respectfully submitted by Kathy Ketchum.